Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Accumulated Depreciation (2017 - 2024)

Historic Accumulated Depreciation for Sutro Biopharma (STRO) over the last 8 years, with Q4 2024 value amounting to $48.6 million.

  • Sutro Biopharma's Accumulated Depreciation rose 1533.81% to $48.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was $48.6 million, marking a year-over-year increase of 1533.81%. This contributed to the annual value of $48.6 million for FY2024, which is 1533.81% up from last year.
  • Per Sutro Biopharma's latest filing, its Accumulated Depreciation stood at $48.6 million for Q4 2024, which was up 1533.81% from $42.2 million recorded in Q4 2023.
  • Over the past 5 years, Sutro Biopharma's Accumulated Depreciation peaked at $48.6 million during Q4 2024, and registered a low of $33.4 million during Q4 2021.
  • Moreover, its 5-year median value for Accumulated Depreciation was $37.9 million (2022), whereas its average is $39.8 million.
  • As far as peak fluctuations go, Sutro Biopharma's Accumulated Depreciation crashed by 923.51% in 2021, and later surged by 1533.81% in 2024.
  • Over the past 5 years, Sutro Biopharma's Accumulated Depreciation (Quarter) stood at $36.8 million in 2020, then dropped by 9.24% to $33.4 million in 2021, then grew by 13.4% to $37.9 million in 2022, then rose by 11.23% to $42.2 million in 2023, then increased by 15.34% to $48.6 million in 2024.
  • Its Accumulated Depreciation stands at $48.6 million for Q4 2024, versus $42.2 million for Q4 2023 and $37.9 million for Q4 2022.